We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
In the latest trading session, Teladoc (TDOC - Free Report) closed at $6.00, marking a +1.35% move from the previous day. This change outpaced the S&P 500's 0.02% loss on the day. Meanwhile, the Dow experienced a drop of 0.35%, and the technology-dominated Nasdaq saw a decrease of 0.15%.
The telehealth services provider's shares have seen a decrease of 8.92% over the last month, not keeping up with the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company is expected to report EPS of -$0.23, down 9.52% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $585.55 million, showing a 6.53% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and revenue of $2.4 billion, which would represent changes of +19.3% and -5.03%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Teladoc presently features a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 101, finds itself in the top 42% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Teladoc (TDOC) Rises As Market Takes a Dip: Key Facts
In the latest trading session, Teladoc (TDOC - Free Report) closed at $6.00, marking a +1.35% move from the previous day. This change outpaced the S&P 500's 0.02% loss on the day. Meanwhile, the Dow experienced a drop of 0.35%, and the technology-dominated Nasdaq saw a decrease of 0.15%.
The telehealth services provider's shares have seen a decrease of 8.92% over the last month, not keeping up with the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company is expected to report EPS of -$0.23, down 9.52% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $585.55 million, showing a 6.53% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and revenue of $2.4 billion, which would represent changes of +19.3% and -5.03%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Teladoc presently features a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 101, finds itself in the top 42% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.